← All Signals

🏥 FDA: K.C. Pharmaceuticals, Inc — Class II

healthcareactionableSource: FDA
90%Confidence
0Views
FDASource
2026-04-17Date

Summary

Dry eye relief products from K.C. Pharmaceuticals show sterility assurance failures affecting Gericare, TopCare, and Rite Aid brands. This pattern suggests the manufacturer's entire eye drop product line may be compromised.

Actionable: Conduct comprehensive testing of all K.C. Pharmaceuticals eye care products and prepare for potential class action litigation.

AI Confidence: 90%

Data Points

firmK.C. Pharmaceuticals, Inc
classificationClass II
statusOngoing
distributionNationwide in the US
productDry Eye Relief Eye Drops, (glycerin 0.2%, hypromellose 0.2% and polyethylene glycol 400 1%) 0.5 FL OZ (15 mL) bottles; a) GERI CARE, Distributed by:

Get Signals Instantly

Premium subscribers receive every signal via Telegram the moment it fires — hours before it appears here.

Subscribe Now